Cargando…

Antiresorptive Agents Increase the Effects of Exercise on Preventing Postmenopausal Bone Loss in Women: A Meta-Analysis

BACKGROUND AND OBJECTIVES: It remains unknown whether the combination of antiresorptive agents and exercise would generate additive effects on bone mineral density (BMD) in postmenopausal women, though their separate roles in preventing bone loss have been well established. This meta-analysis aimed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Renqing, Xu, Zhengang, Zhao, Meihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304813/ https://www.ncbi.nlm.nih.gov/pubmed/25615597 http://dx.doi.org/10.1371/journal.pone.0116729

Ejemplares similares

Comparative effects of antiresorptive agents on bone mineral density and bone turnover in postmenopausal women
por: Jordan, Natasha, et al.
Publicado: (2006)

New Antiresorptive Therapies for Postmenopausal Osteoporosis
por: Choi, Hee-Jeong
Publicado: (2015)

Bone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women’s health practice
por: Cheung, Angela M, et al.
Publicado: (2016)

Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis
por: Rajput, Swati, et al.
Publicado: (2023)

Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
por: Chavassieux, Pascale, et al.
Publicado: (2019)

Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models
por: Paton‐Hough, Julia, et al.
Publicado: (2018)

Protocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal women
por: Bilek, Laura D., et al.
Publicado: (2016)

Antiresorptive Drugs Beyond Bisphosphonates and Selective Oestrogen Receptor Modulators for the Management of Postmenopausal Osteoporosis
por: Reginster, J. Y., et al.
Publicado: (2014)

Combination therapy of anabolic and nonbisphosphonates antiresorptive agents for the treatment of osteoporosis: A meta-analysis
por: Lou, Shenghan, et al.
Publicado: (2017)

Benefits of combined treatments using antiresorptive agents and cytotoxic drugs
por: Holen, I, et al.
Publicado: (2006)

Synergistic effects of cytotoxic drugs and antiresorptive agents in vitro and in vivo
por: Ottewell, PD, et al.
Publicado: (2006)

Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents
por: Rodriguez-Lozano, Francisco-Javier, et al.
Publicado: (2016)

Evaluation of bone loss in diabetic postmenopausal women
por: Karimifar, Mansoor, et al.
Publicado: (2012)

Disulfiram Attenuates Osteoclast Differentiation In Vitro: A Potential Antiresorptive Agent
por: Ying, Hua, et al.
Publicado: (2015)

Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals
por: Cosman, Felicia, et al.
Publicado: (2021)

Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN Trial
por: Lomax, Anna J., et al.
Publicado: (2013)

The influence of antiresorptive bone medication on the effect of high-intensity resistance and impact training on osteoporotic fracture risk in postmenopausal women with low bone mass: protocol for the MEDEX-OP randomised controlled trial
por: Fischbacher, Melanie, et al.
Publicado: (2019)

Immune Regulation of Osteoclast Function in Postmenopausal Osteoporosis: A Critical Interdisciplinary Perspective
por: Zhao, Renqing
Publicado: (2012)

Medication burden of Saudi Arabian women receiving antiresorptive therapy
por: Sadat-Ali, Mir, et al.
Publicado: (2012)

Serotonin reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local antiresorptive effect
por: Ortuño, María José, et al.
Publicado: (2016)

Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis
por: Tanaka, Makoto, et al.
Publicado: (2017)

Antiresorptive agent-related osteonecrosis of the jaw in osteoporosis patients from Asian countries
por: Taguchi, Akira, et al.
Publicado: (2017)

Effects of antiresorptive agents on body composition: a case-control retrospective study
por: Al Khayyat, Suhel Gabriele, et al.
Publicado: (2023)

Effect of whole-body vibration on reduction of bone loss and fall prevention in postmenopausal women: a meta-analysis and systematic review
por: Ma, Chiyuan, et al.
Publicado: (2016)

The Role of Soy Isoflavones in the Prevention of Bone Loss in Postmenopausal Women: A Systematic Review with Meta-Analysis of Randomized Controlled Trials
por: Barańska, Agnieszka, et al.
Publicado: (2022)

Medication-Related Osteonecrosis of the Jaw in Patients Treated Concurrently with Antiresorptive and Antiangiogenic Agents: Systematic Review and Meta-Analysis
por: Srivastava, Akanksha, et al.
Publicado: (2021)

Importance of antiresorptive therapies for patients with bone metastases from solid tumors
por: Talreja, Draupadi B
Publicado: (2012)

Review and Update of the Risk Factors and Prevention of Antiresorptive-Related Osteonecrosis of the Jaw
por: Kim, Ha Young
Publicado: (2021)

Interval exercise increases angiogenic cell function in postmenopausal women
por: Harris, Emma, et al.
Publicado: (2017)

Antiresorptive Agents are More Effective in Preventing Titanium Particle‐Induced Calvarial Osteolysis in Ovariectomized Mice Than Anabolic Agents in Short‐Term Administration
por: Fu, Guangtao, et al.
Publicado: (2018)

Moxibustion as adjuvant therapy for preventing bone loss in postmenopausal women: protocol for a randomised controlled trial
por: Lu, Lingyun, et al.
Publicado: (2022)

Anabolic and antiresorptive actions of locally delivered bisphosphonates for bone repair: A review
por: Qayoom, I., et al.
Publicado: (2018)

Computed tomography bone density variations in oncological patients undergoing antiresorptive medication
por: Yanaguizawa, Wellington Hideaki, et al.
Publicado: (2022)

The efficacy and safety of exercise for prevention of fall-related injuries in older people with different health conditions, and differing intervention protocols: a meta-analysis of randomized controlled trials
por: Zhao, Renqing, et al.
Publicado: (2019)

Exercise Prescription and the Minimum Dose for Bone Remodeling Needed to Prevent Osteoporosis in Postmenopausal Women: A Systematic Review
por: Koshy, Feeba Sam, et al.
Publicado: (2022)

The Efficacy of Bisphosphonates in Preventing Aromatase Inhibitor Induced Bone Loss for Postmenopausal Women with Early Breast Cancer: A Systematic Review and Meta-Analysis
por: Anagha, Pooleriveetil Padikkal, et al.
Publicado: (2014)

Potassium citrate prevents increased osteoclastogenesis resulting from acidic conditions: Implication for the treatment of postmenopausal bone loss
por: Granchi, Donatella, et al.
Publicado: (2017)

TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy
por: Siderova, Mira, et al.
Publicado: (2018)

Prolonged Treatments With Antiresorptive Agents and PTH Have Different Effects on Bone Strength and the Degree of Mineralization in Old Estrogen-Deficient Osteoporotic Rats
por: Cheng, Zhiqiang, et al.
Publicado: (2009)

Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS
por: Anastasilakis, Athanasios D, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t6v1051c4m5ifuk7150onbqmee